Detalhe da pesquisa
1.
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease.
N Engl J Med
; 381(17): 1644-1652, 2019 10 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31597037
2.
The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-ß concentrations and clearance in the cynomolgus monkey.
Toxicol Appl Pharmacol
; 323: 53-65, 2017 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28315356
3.
An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the UBE3A-AS transcript.
Sci Transl Med
; 15(688): eabf4077, 2023 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36947593
4.
Developing antisense oligonucleotides for a TECPR2 mutation-induced, ultra-rare neurological disorder using patient-derived cellular models.
Mol Ther Nucleic Acids
; 29: 189-203, 2022 Sep 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35860385
5.
RNA polymerase II degradation in response to rapamycin is not mediated through ubiquitylation.
Biochem Biophys Res Commun
; 413(2): 248-53, 2011 Sep 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-21884683
6.
Rrd1 isomerizes RNA polymerase II in response to rapamycin.
BMC Mol Biol
; 11: 92, 2010 Dec 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-21129186
7.
Adverse vacuolation in multiple tissues in cynomolgus monkeys following repeat-dose administration of a PEGylated protein.
Toxicol Lett
; 317: 120-129, 2019 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31580884
8.
Personalized antisense oligonucleotides 'for free, for life' - the n-Lorem Foundation.
Nat Med
; 29(6): 1302-1303, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37169866
9.
The Saccharomyces cerevisiae phosphatase activator RRD1 is required to modulate gene expression in response to rapamycin exposure.
Genetics
; 172(2): 1369-72, 2006 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-16322523
10.
ALDH1 as a functional marker of cancer stem and progenitor cells.
Stem Cells Dev
; 18(1): 17-25, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-18573038